Overview
TransMedics develops the Organ Care System (OCS), a portable device that keeps donor organs alive outside the body using warm, oxygenated perfusion, allowing continuous viability monitoring and assessment. It makes money by selling the OCS consoles, selling disposable sets per transplant, and offering the National OCS Program, which provides trained procurement surgeons, clinical support, and dedicated organ transport logistics. The company stands apart by having FDA-approved preservation and assessment for hearts, lungs, and livers, including DBD and DCD indications, and by offering an integrated hardware, disposables, and logistics platform. Its goal is to increase viable transplants and donor organ utilization by improving preservation, assessment, and logistics across transplant centers.
Work here?Claim your company
Simplify's take
What believers are saying
- Q3 2026 revenue reached $203 million, up 41%, and raised full-year guidance.
- October 2026 FDA approvals expanded ENHANCE Heart Part B and DENOVO Lung trials.
- Continued access for ENHANCE Heart adds 90 patients, deepening clinical evidence and future label expansion.
What critics are saying
- July 2026 Massachusetts court kept forced-bundling securities claims alive against Hassanein and Gordon.
- European logistics expansion depends on regulatory approvals, integrations, and PAD Aviation execution through 2027.
- OCS Kidney first human testing starts in 2027; failure leaves TransMedics limited to three organs.
What makes TransMedics unique
- TransMedics owns FDA-approved heart, lung, and liver preservation systems, unlike any rival.
- Its National OCS Program bundles devices, surgeons, logistics, and aircraft into one workflow.
- July 2026 PAD Aviation investment extends the U.S. logistics model into Europe.
Help us improve and share your feedback! Did you find this helpful?
